Investigational Cancer Therapeutics Fellowship

The Investigational Cancer Therapeutics Fellowship provides an exemplary training experience for fellows who wish to become experts in personalized cancer therapies and novel drug development, and prepare fellows for careers as the next generation of independent clinical researchers.

The fellowship offers a one-, two-, or three-year experience in early drug development. Fellows are trained in developing and conducting innovative clinical/translational trials with targeted agents and are prepared for careers in academics, the pharmaceutical industry or government.    

MD Anderson provides a rich experience for fellows. Over 140,000 patients were seen here last year, 45,000 of whom were new patients. Over 10,000 participants were enrolled in more than 1,250 clinical trials exploring innovative treatments. In FY2018, our department alone had over 188 actively enrolling therapeutic trials and enrolled 1,495 patients on our protocols. Nearly half of our active Phase I trials are first-in-human studies.

There is a wealth of opportunity for interactions with a wide variety of investigators who are internationally known for their expertise in basic, translational and/or clinical science. Fellows will learn how to write trials, interact with sponsors, develop translational endpoints to understand drug impact and factors predicting response and host toxicity, present data at national or international meetings, analyze data and write/complete manuscripts.

Eligibility

Program applicants should have:

• M.D. or D.O. degree
• Completed an hematology/oncology fellowship or equivalent training
• An interest in a career in drug development
• Passed the licensure exam (USMLE Steps 1 & 2)
• Foreign-trained applicants must have ECFMG certification